Suppr超能文献

环糊精对难溶性药物口服吸收影响的体内外相关性。

In vitro-in vivo correlation in the effect of cyclodextrin on oral absorption of poorly soluble drugs.

机构信息

Department of Chemistry, Manufacturing and Control, Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Ltd., 6-7-5, Minatojimaminamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.

Department of Chemistry, Manufacturing and Control, Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Ltd., 6-7-5, Minatojimaminamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.

出版信息

Int J Pharm. 2021 May 1;600:120494. doi: 10.1016/j.ijpharm.2021.120494. Epub 2021 Mar 17.

Abstract

In this study the concentration effect of 2-Hydroxypropyl-beta-cyclodextrin (HP-βCyD) on oral drug absorption of the BCS class II drugs Danazol (DNZ) and Albendazole (ABZ) was evaluated. In vitro permeation of solutions and suspension systems was compared with their in vivo intestinal absorption in rats and their in vitro-in vivo correlation assessed. In solutions excess amounts of HP-βCyD decreased both in vitro permeation and in vivo absorption due to the decrease in free drug concentration, as expected. However, in suspension systems the contribution of HP-βCyD by drug complexation was found to be altered by further rate limiting steps for membrane permeation and intestinal absorption of each drug. In vitro permeation of DNZ was rate-limited by the diffusion into the unstirred water layer (UWL), while that of ABZ was rate-limited by the permeation across the lipid membrane. For the in vivo intestinal absorption, both drugs were rate-limited by the dissolution rate from undissolved drug. These differences in the rate-limiting process were considered to cause discrepancies in the result of in vitro and in vivo assays. In conclusion, it is quite important to understand the rate limiting process of oral absorption of the target drug for designing oral liquid formulations containing cyclodextrins.

摘要

本研究评价了 2-羟丙基-β-环糊精(HP-βCyD)对 BCS Ⅱ类药物达那唑(DNZ)和阿苯达唑(ABZ)口服药物吸收的浓度效应。比较了溶液和混悬液系统的体外渗透与大鼠体内肠吸收,并评估了它们的体外-体内相关性。在溶液中,由于游离药物浓度降低,过量的 HP-βCyD 会降低体外渗透和体内吸收,这是预期的结果。然而,在混悬液系统中,HP-βCyD 通过药物络合的贡献被发现受到每种药物通过膜渗透和肠道吸收的进一步限速步骤的改变。DNZ 的体外渗透受未搅动水层(UWL)扩散的限制,而 ABZ 的体外渗透受脂膜渗透的限制。对于体内肠吸收,两种药物的吸收都受到未溶解药物的溶解速率的限制。这些限速过程的差异被认为是导致体外和体内试验结果不一致的原因。总之,对于设计含有环糊精的口服液体制剂,了解目标药物口服吸收的限速过程非常重要。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验